A highly sensitive multiplex immunoassay for inflammatory cytokines in dried blood spots

2020 ◽  
Author(s):  
Thomas W. McDade ◽  
Aaron Miller ◽  
Tina T. Tran ◽  
Ann E. B. Borders ◽  
Greg Miller
Keyword(s):  
Inflammatory Cytokines ◽  
Dried Blood Spots ◽  
Multiplex Immunoassay ◽  
Blood Spots ◽  
Highly Sensitive

scholarly journals A highly sensitive immunoassay for interleukin-6 in dried blood spots

2012 ◽  
Vol 24 (6) ◽  
pp. 863-865 ◽  
Author(s):  
Elizabeth M. Miller ◽  
Thomas W. Mcdade
Keyword(s):  
Interleukin 6 ◽  
Dried Blood Spots ◽  
Blood Spots ◽  
Highly Sensitive

scholarly journals State of the Science in Dried Blood Spots

2018 ◽  
Vol 64 (4) ◽  
pp. 656-679 ◽  
Author(s):  
Jeffrey D Freeman ◽  
Lori M Rosman ◽  
Jeremy D Ratcliff ◽  
Paul T Strickland ◽  
David R Graham ◽  
...  
Keyword(s):  
Systematic Approach ◽  
Full Range ◽  
Dried Blood Spots ◽  
Blood Spots ◽  
Highly Sensitive ◽  
Wide Range ◽  
Potential Applications ◽  
Review Of Reviews ◽  
Near Term ◽  
State Of The Science

Abstract BACKGROUND Advancements in the quality and availability of highly sensitive analytical instrumentation and methodologies have led to increased interest in the use of microsamples. Among microsamples, dried blood spots (DBS) are the most well-known. Although there have been a variety of review papers published on DBS, there has been no attempt at describing the full range of analytes measurable in DBS, or any systematic approach published for characterizing the strengths and weaknesses associated with adoption of DBS analyses. CONTENT A scoping review of reviews methodology was used for characterizing the state of the science in DBS. We identified 2018 analytes measured in DBS and found every common analytic method applied to traditional liquid samples had been applied to DBS samples. Analytes covered a broad range of biomarkers that included genes, transcripts, proteins, and metabolites. Strengths of DBS enable its application in most clinical and laboratory settings, and the removal of phlebotomy and the need for refrigeration have expanded biosampling to hard-to-reach and vulnerable populations. Weaknesses may limit adoption in the near term because DBS is a nontraditional sample often requiring conversion of measurements to plasma or serum values. Opportunities presented by novel methodologies may obviate many of the current limitations, but threats around the ethical use of residual samples must be considered by potential adopters. SUMMARY DBS provide a wide range of potential applications that extend beyond the reach of traditional samples. Current limitations are serious but not intractable. Technological advancements will likely continue to minimize constraints around DBS adoption.

Liquid chromatography-mass spectrometry determination of iloperidone on rat dried blood spots: application to pharmacokinetics

2017 ◽  
Vol 9 (39) ◽  
pp. 5749-5756
Author(s):  
R. Nageswara Rao ◽  
K. Guru Prasad ◽  
Sara Khalid ◽  
K. S. Praneetha ◽  
Dilip Dodda ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Dried Blood Spots ◽  
Liquid Chromatography Mass Spectrometry ◽  
Spectrometry Method ◽  
Mass Spectrometry Method ◽  
Blood Spots ◽  
Chromatography Mass Spectrometry ◽  
Highly Sensitive

A simple, rapid and highly sensitive liquid chromatography-mass spectrometry method was developed and validated for analysis of iloperidone on rat dried blood spots.

Blood-spot thyrotropin radioimmunoassay in a screening program for congenital hypothyroidism.

1979 ◽  
Vol 25 (6) ◽  
pp. 933-938 ◽  
Author(s):  
W A Sadler ◽  
C P Lynskey
Keyword(s):  
Congenital Hypothyroidism ◽  
Screening Program ◽  
Rank Correlation ◽  
Dried Blood Spots ◽  
Recall Rate ◽  
Factors Affecting ◽  
Blood Spots ◽  
Highly Sensitive ◽  
Blood Spot ◽  
Assay Conditions

Abstract We describe a highly sensitive and precise radioimmunoassay for thyrotropin in dried blood spots on filter paper cards. In a screening program for congenital hypothyroidism, blood-spot thyrotropin concentrations are measured in infants whose blood-spot thyroxine concentrations are in the lower 10%, and this strategy has reduced the recall rate from 1.7% (thyroxine assay alone) to 0.17%. Thyrotropin assay samples consist of discs 4.5-mm in diameter, containing about 6 microL of blood, punched from blood spots. By appropriate attention to assay conditions, a mean least-detectable thyrotropin concentration equivalent to 2.5 milliunits/L plasma has been achieved. Concomitant measurement of thyrotropin by plasma and blood-spot assays in 91 subjects yielded a Spearman rank correlation coefficient of 0.9732. An analysis of variance of the distribution volume of thyrotropin in blood spots and a covariance analysis of factors affecting blood-spot thyroxine results are presented.

Therapeutic drug monitoring (TDM) of the recent antipsychotic ziprasidone in dried blood spots (DBS) and plasma

2011 ◽  
Vol 44 (06) ◽  
Author(s):  
L Mercolini ◽  
G Fulgenzi ◽  
M Melis ◽  
G Boncompagni ◽  
LJ Albers ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Dried Blood Spots ◽  
Therapeutic Drug ◽  
Blood Spots

scholarly journals Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Niclas Roxhed ◽  
Annika Bendes ◽  
Matilda Dale ◽  
Cecilia Mattsson ◽  
Leo Hanke ◽  
...  
Keyword(s):  
Immune Response ◽  
Dried Blood Spots ◽  
Serological Testing ◽  
S Protein ◽  
Individual Level ◽  
Blood Spots

AbstractSerological testing is essential to curb the consequences of the COVID-19 pandemic. However, most assays are still limited to single analytes and samples collected within healthcare. Thus, we establish a multianalyte and multiplexed approach to reliably profile IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots (DBS). We analyse DBS collected during spring of 2020 from 878 random and undiagnosed individuals from the population in Stockholm, Sweden, and use classification approaches to estimate an accumulated seroprevalence of 12.5% (95% CI: 10.3%–14.7%). This includes 5.4% of the samples being IgG+IgM+ against several SARS-CoV-2 proteins, as well as 2.1% being IgG−IgM+ and 5.0% being IgG+IgM− for the virus’ S protein. Subjects classified as IgG+ for several SARS-CoV-2 proteins report influenza-like symptoms more frequently than those being IgG+ for only the S protein (OR = 6.1; p < 0.001). Among all seropositive cases, 30% are asymptomatic. Our strategy enables an accurate individual-level and multiplexed assessment of antibodies in home-sampled blood, assisting our understanding about the undiagnosed seroprevalence and diversity of the immune response against the coronavirus.

Sign in / Sign up

Export Citation Format

Share Document